Intestinal methanogen overgrowth and its impact on gastrointestinal disorders in children: a retrospective study Authors: Runjie Wang, Ruixue Wang, Yongmei Xiao, Xiaolu Li, Ting Ge, Ronghua Yu, Ting Song, Chenling Yuan, Ting Zhang Published: 2025 ABSTRACT AbstractObjectiveIntestinal methanogen overgrowth (IMO) is increasingly recognized as a contributor to gastrointestinal symptoms in children. This study aimed to investigate the clinical characteristics and endoscopic features of pediatric patients with IMO.MethodsA retrospective analysis was conducted on children with gastrointestinal symptoms hospitalized in the Department of Gastroenterology, Shanghai Children’s Hospital, from September 2021 to November 2022. Patients were stratified into IMO positive and IMO negative groups based on lactulose methane breath test (LBT) results, followed by a comparative analysis of clinical characteristics between the groups. Among them, 102 patients who underwent gastroscopy and/or colonoscopy were included for analysis of endoscopic and histopathological features. Clinical information was obtained from electronic medical records.ResultsAmong 124 children with gastrointestinal symptoms, 79 (63.7%) were IMO positive. Compared to the IMO negative group (n = 45), the IMO positive group had a lower proportion of diarrhea, with a statistically significant difference (P < 0.05). Villous blunting in the terminal ileal mucosa was more prevalent in the IMO positive group (P < 0.05). No significant differences were observed in nutritional status between groups. Of 70 children ultimately diagnosed with functional gastrointestinal disorders (FGID), 48 (68.6%) were IMO positive. Among FGID patients, age distribution differed significantly between IMO positive and IMO negative groups (P < 0.05), with school-aged children predominating in the IMO positive group compared to preschool-aged and adolescent children.ConclusionsIMO positivity is prevalent in children with gastrointestinal symptoms, particularly prominent among those with FGID. The IMO positive group exhibited a lower incidence of diarrhea and more frequently demonstrated terminal ileal villous blunting. In FGID patients, IMO positivity correlates with age, showing higher rates in school-aged children.Keywords: Intestinal methanogen overgrowth, Small intestinal bacterial overgrowth, Gastrointestinal disease, Lactulose breath test, Children Introduction The intestinal microbiota comprises diverse microbial communities, including bacteria, viruses, fungi, archaea, and protozoa, all of which play critical roles in maintaining gut homeostasis and influencing disease pathogenesis. Dysbiosis, characterized by an imbalance in microbial composition, has been implicated in a spectrum of gastrointestinal disorders. Notably, small intestinal bacterial overgrowth (SIBO) is strongly associated with conditions such as irritable bowel syndrome (IBS), chronic diarrhea, and functional dyspepsia (FD) [1]. Recent advancements in diagnostic technologies have highlighted the clinical relevance of IMO, a condition marked by excessive proliferation of methane-producing archaea. Emerging evidence indicates that approximately 30% of SIBO patients exhibit concurrent IMO, while elevated IMO positivity rates are independently observed in individuals with functional constipation (FC) and inflammatory bowel disease (IBD) [2]. These findings suggest that IMO may contribute to distinct pathophysiological pathways in gastrointestinal dysfunction, though its mechanistic underpinnings remain poorly elucidated. IMO is defined as the overgrowth of methanogenic archaea (e.g., Methanobrevibacter smithii), which utilize hydrogen (H2) derived from carbohydrate fermentation to synthesize methane (CH4), thereby altering gut motility and function [3, 4]. Conventional microbial culture methods fail to detect methanogens due to their strict anaerobic requirements, necessitating non-invasive diagnostic approaches. The 2017 North American Consensus Guidelines and 2020 ACG clinical guideline established the lactulose methane breath test (LBT) as the gold standard for IMO diagnosis, with a threshold of CH4 ≥ 10 ppm at any time point [1, 5]. LBT offers the advantages of simplicity, rapidity, and high acceptability, particularly in pediatric populations where invasive procedures are often impractical. Clinically, IMO is linked to a variety of gastrointestinal diseases, including IBS, FD, and functional abdominal pain, with the strongest association observed in FC [6]. Methane has been shown to directly inhibit intestinal smooth muscle contraction, prolonging colonic transit time. Additionally, symptoms such as bloating and abdominal pain in IMO patients may arise from methane-induced luminal distension and localized inflammatory responses [7]. Despite these insights, research focusing on children remains scarce, and the correlation between IMO and endoscopic mucosal abnormalities in this demographic is yet to be clarified. Although adult studies have partially delineated the clinical features of IMO, significant gaps persist in pediatric epidemiological data and pathophysiological mechanisms. To date, no systematic studies have reported the prevalence of IMO or its association with gastrointestinal symptoms and endoscopic findings among children. This study aims to bridge this knowledge gap by analyzing LBT results and endoscopic data to investigate the prevalence, clinical characteristics, and mucosal correlates of IMO in pediatric patients, thereby providing novel insights for targeted diagnostic and therapeutic strategies. Materials and methods Study population This retrospective analysis involved 124 children from the Gastroenterology Department of our hospital, conducted from September 2021 to November 2022. The inclusion criteria were as follows: (1) All participants underwent a lactulose methane breath test; (2) They exhibited gastrointestinal symptoms lasting for at least two months, which included poor appetite, abdominal pain, abdominal distension, diarrhea, constipation, nausea, and vomiting. (3) Participants were aged between 3 and 18 years; (4) All participants were evaluated with blood examination, stool tests, abdominal CT or B-ultrasound, and other necessary examinations based on their symptoms. The exclusion criteria were as follows: (1) individuals who had taken antibiotics within the past month; (2) individuals who consumed probiotics or acid-suppressing medications like proton pump inhibitors within one week; (3) individuals who had used laxatives within one week; (4) individuals with an inability to accomplish the LBT; and (5) individuals with peptic ulcer, primary immunodeficiency disease, celiac disease, inflammatory bowel disease, and a history of gastrointestinal surgery. Approval for the study was granted by the Ethics Review Committee of Shanghai Children’s Hospital (approval number: 2024R058-E02). Clinical data The following information was collected from the electronic medical record during the clinical visit: (1) The child’s age and gender, with patients were divided into three age groups: preschool age (3 to 6 years), elementary school age (7 to 12 years), and adolescents (13 to 18 years); (2) weight and height; (3) gastrointestinal symptoms; and (4) The endoscopic appearance and histological evaluation. Endoscopic appearance and histological evaluation A total of 102 patients underwent gastroscopy and/or colonoscopy examinations to evaluate the endoscopic appearance and identify any structural abnormalities. Mucosal inflammation was characterized by congestion, edema, erosion, and lymphoid follicular hyperplasia in the duodenal and terminal ileal mucosa. Mucosal biopsies were performed on the upper and/or lower gastrointestinal tracts. The biopsy samples were processed through formalin fixation, paraffin embedding, and subsequent staining with hematoxylin-eosin (HE) for histopathological analysis, with all pathological specimens confirmed by pathologists. Two pathologists jointly assessed the biopsies for the following features: acute inflammation, chronic inflammation, eosinophil count, lymphocytic infiltration, villous length in the small intestine, and the number of crypts. Breath testing All participating children underwent a lactulose breath test (LBT) to detect the levels of exhaled methane to detect IMO. Before the test, all children were required to fast for 12 h, although a limited quantity of water was permitted. During the procedure, children needed to remain awake, quiet, and fasting. A breath hydrogen analyzer, specifically designed and manufactured by Wuxi Shangwo Medical Electronics Co., was used to analyze the levels of hydrogen and methane in the breath samples. After calibrating with standard gas, the fasting baseline levels of hydrogen and methane were established. Subsequently, the child was instructed to quickly consume 10g of lactulose oral solution, with breath samples collected every 30 min, resulting in three collections. The concentrations of hydrogen and methane in the breath were measured and recorded at each interval up to 90 min, leading to the creation of curves depicting hydrogen and methane abundance over time. The diagnosis IMO is confirmed based on the methane (CH4) criteria established by the 2017 North American Consensus Guidelines and the 2020 ACG clinical guideline. A rise of 10ppm or more in CH4 at any point during the test qualifies as a positive result for CH4. Children were divided into the IMO positive group and the IMO negative group based on the CH4 criteria. Statistical analysis In this study, GraphPad Prism 9.5 graphing software was utilized for figure plotting and SPSS 19.0 statistical software for data analysis. Descriptive statistics, including frequency distributions of continuous and categorical variables, were computed for both the IMO positive and IMO negative groups. Continuous variables following a normal distribution were expressed as mean ± standard deviation (x ± s), with intergroup comparisons conducted using one-way analysis of variance (ANOVA). Categorical data were presented as frequency (percentage), with group comparisons performed via chi-square test (χ²) or Fisher’s exact test. Binary logistic regression analysis was applied to assess independent risk factors. A p-value of less than 0.05 was considered statistically significant across all analyses. Results A total of 124 children were enrolled in the study, with ages ranging from 3.57 to 15.78 years. Among these, 62 (50.0%) were male and 62 (50.0%) were female. Of the children, 45 (36.3%) were regarded as the IMO negative group, while 79 (63.7%) were classified as the IMO positive group based on the CH4 criteria. Significant differences were observed in the exhaled levels of CH4 between children with IMO positive and IMO negative results from 0 to 90-minute intervals (Fig. 1). Exhaled breath CH4 demonstrated an aggregation trend, showing elevated levels at all time points. A baseline elevation was identified in 51.9% (41/79) of IMO positive pediatric patients, indicating that IMO may be identifiable prior to lactose ingestion (Fig. 2). Comparison of exhaled CH₄ levels (ppm) between children with IMO positivity and IMO negativity (*: P < 0.05, **: P < 0.01, ***: P < 0.001, ****: P < 0.0001) Distribution of the number of IMO positive cases at different time points Table 1 summarizes the comparison of the demographic characteristics and clinical manifestations between IMO positive and IMO negative children. The median age of IMO positive children was lower than that of IMO negative children, which were 9.72 (7.45, 12.28) years and 10.92 (7.31, 13.21) years, respectively. No significant differences were observed between IMO positive and IMO negative groups regarding gender, age, and nutritional status. The IMO positive rates for loss of appetite, constipation, bloating, abdominal pain, and nausea/vomiting were 83.3% (5/6), 78.3% (18/23), 67.7% (21/31), 63.1% (53/84), and 61.1% (11/18), respectively, with no significant differences observed. In contrast, the IMO positive rate was lower in children with diarrhea (36.8%, 7/19), and this difference was statistically significant (P = 0.011). Table 1Comparison of clinical and demographic features between 124 IMO positive and IMO negative childrenCharacteristicsTotal (N = 124, %)IMO negative (N = 45, %)IMO positive (N = 79, %)Statistics Male 62 (50)21 (46.7)41 (51.9)x2 = 0.31P = 0.709Age [years, M (Q1, Q3)]10.02 (7.48, 12.75)10.92 (7.31, 13.21)9.72 (7.45, 12.28)Z=−0.99P = 0.321 Age grouping Preschool-age15 (12.1)4 (8.9)11 (13.9)x2 = 4.88P = 0.094 School-age69 (55.6)21 (46.7)48 (60.8) Adolescence40 (32.3)20 (44.4)20 (25.3) Nutritional status Height-age Z Score[M (Q1, Q3)]0.63(−0.13, 1.28)0.52(−0.26, 1.26)0.65(0.00, 1.35)Z = 0.98P = 0.327 Weight-age Z score[M (Q1, Q3)]0.04(−0.86, 0.79)−0.05(−0.92, 0.69)0.15(−0.84, 0.83)Z = 0.82P = 0.412 Weight-height Z Score[M (Q1, Q3)]−0.50(−1.58, 0.56)−1.01(−1.44, 0.32)−0.19(−1.68, 0.63)Z = 0.85P = 0.394 Gastrointestinal Symptoms Loss of appetite6 (4.8)1 (16.7)5 (83.3)—P = 0.416 Constipation23 (18.5)5 (21.7)18 (78.3)x2 = 2.59P = 0.150 Bloating31 (25.0)10 (32.3)21 (67.7)x2 = 0.29P = 0.669 Abdominal pain84 (67.7)31 (36.9)53 (63.1)x2 = 0.04P = 0.845 Nausea/Vomiting18 (14.5)7 (38.9)11 (61.1)x2 = 0.06P = 1.000 Diarrhea19 (15.3)12 (63.2)7 (36.8)x2 = 7.00P = 0.011*IMO Intestinal methanogen overgrowth. (*: P < 0.05) Comparison of clinical and demographic features between 124 IMO positive and IMO negative children x2 = 0.31 P = 0.709 Z=−0.99 P = 0.321 x2 = 4.88 P = 0.094 Height-age Z Score [M (Q1, Q3)] 0.63 (−0.13, 1.28) 0.52 (−0.26, 1.26) 0.65 (0.00, 1.35) Z = 0.98 P = 0.327 Weight-age Z score [M (Q1, Q3)] 0.04 (−0.86, 0.79) −0.05 (−0.92, 0.69) 0.15 (−0.84, 0.83) Z = 0.82 P = 0.412 Weight-height Z Score [M (Q1, Q3)] −0.50 (−1.58, 0.56) −1.01 (−1.44, 0.32) −0.19 (−1.68, 0.63) Z = 0.85 P = 0.394 — P = 0.416 x2 = 2.59 P = 0.150 x2 = 0.29 P = 0.669 x2 = 0.04 P = 0.845 x2 = 0.06 P = 1.000 x2 = 7.00 P = 0.011* IMO Intestinal methanogen overgrowth. (*: P < 0.05) Table 2 presents the independent risk factor analysis for IMO positive children. Based on the statistics from the Table 1, we included age grouping (P = 0.094) and diarrhea (P = 0.011) in the analysis. The results suggest a significant impact of diarrhea on the development of IMO positive (P = 0.017). The findings indicate that diarrhea may be a protective factor against intestinal methanogen overgrowth. Table 2Independent risk factor analysis of 79 IMO positive childrenBStd. ErrorWaldDegrees of FreedomSignificanceExp(B)95% CI for Exp(B)Lower limitUpper limitPreschool-age0.8750.6771.67410.1962.4000.6379.042School-age0.8000.4223.59510.0582.2260.9735.090Diarrhea1.2660.5315.69710.017*3.5481.25410.037IMO Intestinal methanogen overgrowth. (*: P < 0.05) Independent risk factor analysis of 79 IMO positive children IMO Intestinal methanogen overgrowth. (*: P < 0.05) Table 3; Fig. 3 show the endoscopic and histopathological features of the terminal ileum and duodenal mucosa. As indicated in Tables 3 and 102 children underwent gastroscopy and/or colonoscopy examinations. Endoscopy reports showed that the mucosa of the duodenum and terminal ileum frequently exhibited normal or mild inflammation. Compared with the IMO negative group, the duodenum appeared normal during endoscopy (46.9%, 30/64) in the IMO positive group, while mild inflammation was predominantly observed in the terminal ileum during endoscopy (67.3%, 33/49). However, no statistical difference was noted between the two groups. Biopsy histopathology revealed varying degrees of lymphocytic infiltration in the duodenal and terminal ileal mucosa of all 102 children. Compared to children with IMO negativity, those with IMO positivity were more likely to exhibit flattened villi and reduced crypts. In the terminal ileum, 32 cases in the IMO positive group demonstrated flattened villi (32/49, 65.3%, P = 0.022), indicating a statistically significant difference. However, these changes were not significantly different in the duodenal biopsy. Additionally, no significant differences were observed between the two groups in acute active inflammation and eosinophil counts in the mucosa. Table 3Comparison of endoscopic and histopathological features between 102 IMO positive and IMO negative childrenCharacteristicsTotal (N, %)IMO negative (N, %)IMO positive (N, %)Statistics Endoscopic appearance of the duodenal mucosa N = 9430 (31.9)64 (68.1) Normal43 (45.7)13 (43.3)30 (46.9)x2 = 0.28P = 0.878 Inflammation34 (36.2)12 (40.0)22 (34.4) Shallow ulcers17 (18.1)5 (16.7)12 (18.8) Histopathological features of the duodenal biopsies Villi blunting27 (28.7)8 (26.7)19 (29.7)x2 = 0.09P = 0.812 Crypt loss23 (24.5)7 (23.3)16 (25.0)x2 = 0.03P = 1.000 Active inflammation12 (12.8)3 (10.0)9 (14.1)—P = 0.746 Number of eosinophils(/HPF)[M (Q1, Q3)]8.00(5.00, 10.00)6.50(4.75, 10.50)8.00(5.00, 10.00)Z = 0.22P = 0.828 Endoscopic appearance of the terminal ileum mucosa N = 7223 (31.9)49 (68.1) Normal26 (36.1)11 (47.8)15 (30.6)—P = 0.232 Inflammation44 (61.1)11 (47.8)33 (67.3) Shallow ulcers2 (2.8)1 (4.3)1 (2.0) Histopathological features of the terminal ileum biopsies Villi blunting40 (55.6)8 (34.8)32 (65.3)x2 = 5.91P = 0.022* Crypt loss49 (68.1)13 (56.5)36 (73.5)x2 = 2.07P = 0.181 Active inflammation25 (34.7)10 (43.5)15 (30.6)x2 = 1.14P = 0.302 Number of eosinophils(/HPF)[M (Q1, Q3)]9.00(5.25, 15.00)10.00(8.00, 18.00)9.00(5.00, 12.00)Z=−1.43P = 0.154IMO Intestinal methanogen overgrowth. (*: P < 0.05) Comparison of endoscopic and histopathological features between 102 IMO positive and IMO negative children x2 = 0.28 P = 0.878 x2 = 0.09 P = 0.812 x2 = 0.03 P = 1.000 — P = 0.746 Number of eosinophils(/HPF) [M (Q1, Q3)] 8.00 (5.00, 10.00) 6.50 (4.75, 10.50) 8.00 (5.00, 10.00) Z = 0.22 P = 0.828 — P = 0.232 x2 = 5.91 P = 0.022* x2 = 2.07 P = 0.181 x2 = 1.14 P = 0.302 Number of eosinophils(/HPF) [M (Q1, Q3)] 9.00 (5.25, 15.00) 10.00 (8.00, 18.00) 9.00 (5.00, 12.00) Z=−1.43 P = 0.154 IMO Intestinal methanogen overgrowth. (*: P < 0.05) Endoscopic and pathological features in two IMO positive children. A1 Endoscopy in an IMO positive child reveals terminal ileal mucosa with normal appearance B1: Endoscopy in another IMO positive child shows mild mucosal erosion in the terminal ileum (yellow arrow) A2, B2: Histopathological features of terminal ileal mucosal biopsies demonstrate increased lymphocytes and plasma cells in the lamina propria, along with partial villous blunting and crypt loss (HE staining, ×100) A3, B3: Occasional neutrophil (green arrow) and eosinophil (red arrow) infiltration observed in the terminal ileum (HE staining, ×400) Among 124 children, 70 were ultimately diagnosed with FGID, classified into three subtypes: FD (n = 28), FC (n = 13), and IBS (n = 29). Table 4 summarizes the comparison of demographic characteristics and clinical manifestations between IMO positive and IMO negative groups diagnosed with FGID. The prevalence of IMO positivity was significantly higher in children with FGID, reaching 68.6% (48/70). The prevalence of IMO positivity was associated with age, with school-aged children exhibiting the highest positivity rate (70.8%, 34/48), followed by adolescents (20.8%, 10/48) and preschool-aged children (8.3%, 4/48). Among specific FGID subtypes, FC had the highest IMO positivity rate (84.6%, 11/13), while IBS had the lowest (55.2%, 16/29). Notably, IBS with diarrhea-predominant subtype (IBS-D) exhibited a higher rate of IMO negativity. Table 4Comparison of clinical and demographic features between 70 children diagnosed with FGIDCharacteristicsTotal (N = 70, %)IMO negative (N = 22, %)IMO positive (N = 48, %)Statistics Male 34 (48.6)9 (40.9)25 (52.1)x2 = 0.75P = 0.446Age [years, M (Q1, Q3)]9.98(7.94, 13.09)12.43(9.18, 13.83)9.39(7.79, 11.45)Z = 3.15P = 0.024* Age grouping Preschool-age4 (5.7)0 (0.0)4 (8.3)—P = 0.017* School-age44 (62.9)10 (45.5)34 (70.8) Adolescence22 (31.4)12 (54.5)10 (20.8) Nutritional status Height-age Z Score[M (Q1, Q3)]0.79(0.00, 1.34)1.00(0.16, 1.34)0.66(0.00, 1.39)Z = 0.94P = 0.903 Weight-age Z score[M (Q1, Q3)]0.15(−0.78, 0.86)0.16(−0.70, 1.35)0.15(−0.79, 0.82)Z = 1.26P = 0.828 Weight-height Z Score[M (Q1, Q3)]−0.60(−1.47, 0.48)−0.79(−1.43, 1.48)−0.52(−1.56, 0.43)Z = 1.50P = 0.818 Gastrointestinal Symptoms Loss of appetite2 (2.9)0 (0.0)2 (100.0)—P = 1.000 Constipation16 (22.9)4 (25.0)12 (75.0)x2 = 0.40P = 0.563 Bloating18 (25.7)3 (16.7)15 (83.3)x2 = 2.45P = 0.148 Abdominal pain52 (74.3)17 (32.7)35 (67.3)x2 = 0.15P = 0.776 Nausea/Vomiting6 (8.6)2 (33.3)4 (66.7)—P = 1.000 Diarrhea12 (17.1)7 (58.3)5 (41.7)—P = 0.041* Diagnosis FD28 (40.0)7 (25.0)21 (75.0)x2 = 0.90P = 0.434 FC13 (18.6)2 (15.4)11 (84.6)—P = 0.204 IBS29 (41.4)13 (44.8)16 (55.2)x2 = 4.13P = 0.042* IBS-C8 (11.4)3 (37.5)5 (62.5)—P = 0.700 IBS-D15 (21.4)8 (53.3)7 (46.7)—P = 0.059 IBS-M3 (4.3)2 (66.7)1 (33.3)—P = 0.231 IBS-U3 (4.3%)0 (0.0)3 (100.0)—P = 0.547IMO Intestinal methanogen overgrowth, FGID Functional gastrointestinal disorders, FD Functional dyspepsia, FC Functional constipation, IBS Irritable bowel syndrome, IBS-C Irritable bowel syndrome with predominant constipation, IBS-D Irritable bowel syndrome with predominant diarrhea, IBS-M Irritable bowel syndrome with mixed bowel habits, IBS-U Irritable bowel syndrome unclassified. (*: P < 0.05) Comparison of clinical and demographic features between 70 children diagnosed with FGID x2 = 0.75 P = 0.446 9.98 (7.94, 13.09) 12.43 (9.18, 13.83) 9.39 (7.79, 11.45) Z = 3.15 P = 0.024* — P = 0.017* Height-age Z Score [M (Q1, Q3)] 0.79 (0.00, 1.34) 1.00 (0.16, 1.34) 0.66 (0.00, 1.39) Z = 0.94 P = 0.903 Weight-age Z score [M (Q1, Q3)] 0.15 (−0.78, 0.86) 0.16 (−0.70, 1.35) 0.15 (−0.79, 0.82) Z = 1.26 P = 0.828 Weight-height Z Score [M (Q1, Q3)] −0.60 (−1.47, 0.48) −0.79 (−1.43, 1.48) −0.52 (−1.56, 0.43) Z = 1.50 P = 0.818 — P = 1.000 x2 = 0.40 P = 0.563 x2 = 2.45 P = 0.148 x2 = 0.15 P = 0.776 — P = 1.000 — P = 0.041* x2 = 0.90 P = 0.434 — P = 0.204 x2 = 4.13 P = 0.042* — P = 0.700 — P = 0.059 — P = 0.231 — P = 0.547 IMO Intestinal methanogen overgrowth, FGID Functional gastrointestinal disorders, FD Functional dyspepsia, FC Functional constipation, IBS Irritable bowel syndrome, IBS-C Irritable bowel syndrome with predominant constipation, IBS-D Irritable bowel syndrome with predominant diarrhea, IBS-M Irritable bowel syndrome with mixed bowel habits, IBS-U Irritable bowel syndrome unclassified. (*: P < 0.05) In this study, all 124 children received treatment for their primary diseases. For instance, eosinophilic gastroenteritis was treated with oral steroids, and constipated populations were provided with stool softening therapy. Additionally, Upper gastrointestinal tract erosions or ulcerations were treated with L-glutamine and sodium gualenate granules to protect the gastric mucosa and/or proton pump inhibitors (PPIs) for acid suppression. Children who tested positive for IMO received a low FODMAP diet for 2–4 weeks. Except for H. pylori-infected patients who received standard triple therapy (amoxicillin + metronidazole/clarithromycin + omeprazole), all IMO positive patients underwent 10-day rifaximin treatment. Among these patients, two remained unresponsive to initial therapy and subsequently underwent fecal microbiota transplantation (FMT), following which they experienced significant symptom improvement. Discussion The current study indicates that IMO is relatively common in children with gastrointestinal diseases, with a notably higher incidence observed in FGID. Moreover, IMO is associated with villous blunting in the terminal ileum. To our knowledge, this is the first report establishing a correlation between IMO and biopsy findings in children with gastrointestinal diseases. Recent studies have demonstrated a strong association between IMO and various gastrointestinal symptoms [8, 9]. In our study, the gastrointestinal symptoms included poor appetite, abdominal pain, abdominal distension, diarrhea, constipation, nausea, and vomiting. The IMO positivity rate in children with diarrhea was 36.8% (7/19), which is significantly lower than the rate observed in children with constipation, at 78.3% (18/23). This finding is consistent with the research conducted by Gandhi et al. [10] and Mehravar et al. [11], which indicated that IMO is significantly associated with constipation, with methane levels positively correlated with IBS-C and inversely correlated with IBS-D. Such an observation may be related to the delayed small bowel and colonic transit time caused by the overgrowth of methanogenic bacteria [12]. Decreased intestinal motility may facilitate the proliferation of methanogenic bacteria, leading to an excess of methanogens produced by archaea, which can induce sensations of satiety or early fullness after eating. Additionally, small intestinal contractile activity may be augmented, and the contractile amplitude may also increase in the ileal muscle, resulting in pain for patients [13, 14]. Abdominal pain, abdominal distension, and constipation may be triggered by an increase in methane gas within the intestine, coupled with a reduction in intestinal motility. This suggests that diarrhea may serve as a protective factor against IMO. FD, FC, and IBS are commonly evaluated as linked to IMO among FGID. Research shows that the positivity rates of IMO in children with FD, FC, and IBS are 32.0%, 35.5%, and 17.1%, respectively [15]. In our study, the positivity rate of IMO among children with FGID was 68.6% (48/70), with positivity rates for FD, FC, and IBS being 75.0% (21/28), 84.6% (11/13), and 55.2% (16/29), respectively. These rates are significantly higher than those reported in other studies, which may be attributed to the relatively small sample size of our study, dietary habits, and regional differences [16]. Currently, data on IMO in children are limited, and future research should involve larger-scale randomized controlled trials. Studies have shown that SIBO is associated with enterocyte injury in the duodenum [17, 18], leading to intestinal damage that can result in villous blunting of the duodenal mucosa and gastrointestinal symptoms [17, 19]. Research has shown that the excessive growth of methanogens can lead to dysbiosis of the gut microbiota and reduced intestinal motility [20]. This condition may trigger bacteria to become endoparasites and increase the contact time between the intestinal mucosa and toxic metabolic end products, including H2S [21–23]. Consequently, this may facilitate translocation of bacteria and absorption of toxic metabolic end products by the intestinal epithelium or induce damage to the intestinal epithelial barrier, thereby exacerbating the inflammatory response within the human gut [24]. Research indicates that IMO may reduce nutrient digestion and absorption, further contributing to growth stunting in infants [25, 26]. However, our study did not find a significant association between duodenal mucosa damage and IMO. A notable finding in our cohort pertains to IMO induced terminal mucosal damage, as evidenced by villus blunting. Studies have revealed distinct differences in the composition of gut microbiota between the upper and lower digestive tracts in humans. The duodenum is predominantly colonized by aerobic or facultative anaerobic bacteria, while the terminal ileum is mainly inhabited by strict anaerobes. The colon serves as the primary habitat for methanogens [27]. Due to its proximity to the colon, the terminal ileum harbors methanogens. In contrast, the duodenum, characterized by high oxygen levels and acidic conditions, is not conducive to the presence of methanogens. The differences in bacterial composition between the duodenal and ileal mucosa may partly account for the discrepancies in our research findings. Methanogens are strict anaerobes that thrive in low-oxygen conditions. The relatively anaerobic environment of the terminal ileum promotes the growth of anaerobic bacteria, increasing susceptibility to colonization [28]. This region is characterized by a dense and complex microbiota ecosystem, which plays a significant role in various physiological and pathological processes [29]. Dysbiosis of methanogenic archaea has been linked to a reduction in short-chain fatty acids (SCFAs) levels, potentially affecting interactions between the microbiota and the intestinal mucosa or immune cells, as well as the overall inflammatory profile of the gut [30, 31]. Moreover, research indicates that the presence of methanogens, coupled with decreased gut motility, increases mucosal exposure to toxic metabolic byproducts, such as hydrogen sulfide (H2S), which can damage the intestinal epithelial barrier [24]. Collectively, these factors contribute to impaired nutrient absorption and the emergence of gastrointestinal symptoms. Clinicians should consider the potential impact of IMO when evaluating the causes of gastrointestinal diseases, as it may serve as a non-invasive alternative to endoscopy for monitoring gastrointestinal tract health in the future. Current treatments for IMO often involve a low FODMAP diet, probiotics, and antibiotics [32, 33], with rifaximin and metronidazole being the most commonly utilized antibiotics in pediatric populations [34]. While rifaximin is generally effective, its efficacy can be influenced by several factors, including drug dosage, treatment duration, and the individual patient’s specific conditions [35, 36]. In our study, four children who did not respond to antibiotic treatment during the 3-month follow-up underwent repeat endoscopy and mucosal biopsy. Two of them were ultimately diagnosed with eosinophilic gastroenteritis. The third and fourth children, diagnosed with FD, experienced significant alleviation of gastrointestinal symptoms following FMT, thereby demonstrating the potential effectiveness of this novel therapeutic regimen for the treatment of IMO. However, it is important to note that this observation is based on a limited number of cases and necessitates validation through larger controlled studies. Numerous studies have demonstrated that FMT exerts therapeutic effects by restoring gut microbiota homeostasis in the host [37, 38]. We hypothesize that FMT may alleviate IMO through similar mechanisms, specifically by reducing the abundance of methanogenic archaea, such as Methanobrevibacter smithii. However, limited evidence exists regarding the efficacy of FMT in targeting IMO associated methanogenesis, and the underlying molecular and ecological mechanisms remain to be elucidated. While our study has revealed new insights, it is essential to acknowledge several limitations. As a single-center retrospective study, our findings may be susceptible to selection bias. The cohort consisted exclusively of hospitalized children with recurrent and refractory gastrointestinal symptoms. This limitation affects the generalizability of our results to the broader pediatric population. Additionally, the lack of follow-up IMO tests and endoscopic examinations for children who exhibited symptom improvement hinders our ability to establish causality or assess long-term outcomes. Future prospective, multi-center studies are necessary to address these limitations. Conclusions In the present study, we retrospectively analyzed the characteristics of children with IMO and the value of the lactulose methane breath test in pediatric patients with gastrointestinal disorders. Our findings contribute to the emerging understanding of IMO by describing the associated histopathological features of villous blunting in the terminal ileum. In the future, the lactulose methane breath test may serve as a valuable tool to detect the health of the gut in pediatric patients with gastrointestinal disorders. Additionally, modulating the gut microbiome may offer an alternative therapeutic option for IMO positive pediatric patients who do not experience symptom relief with the low FODMAP diet along with rifaximin treatment. Acknowledgements The authors thank the family for participating in and supporting this study. Abbreviations Intestinal methanogen overgrowth Small intestinal bacterial overgrowth Fecal microbiota transplantation Lactulose breath test Functional dyspepsia Helicobacter pylori infection Irritable bowel syndrome Eosinophilic gastrointestinal disorder The breath test Functional abdominal pain Hematoxylin-eosin Hydrogen Methane Parts per million Short chain fatty acids Hydrogen sulfide Authors’ contributions RJW and RXW designed the study. RJW and RXW drafted the manuscript. RJW, RXW, YMX, TG, RHY, TS, and CLY acquired, analyzed, and interpreted the data. RJW, RXW, and TZ edited the manuscript. All authors agreed to be accountable for all aspects of the work. Funding National Natural Science Foundation of China (8247031679). Data availability The raw data supporting the conclusions of this manuscript will be made available by the authors without undue reservation to any qualified researcher. Declarations Ethics approval and consent to participate Written informed consent was obtained from the parents of the patients for the genetic study and publication of this study. The study was approved by the Regional Ethical Review Board in Shanghai Children’s Hospital. Consent for publication All authors have read and approved the content, and they agree to submit it for consideration for publication in the journal. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Runjie Wang and Ruixue Wang contributed equally to this work and should be considered co-first authors. References Associated Data Data Availability Statement The raw data supporting the conclusions of this manuscript will be made available by the authors without undue reservation to any qualified researcher.